Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation

Expert Review of Clinical Immunology

Volumn 7, Issue 4, 2011, Pages 429-436

  Congly, Stephen E ^a   Burak, Kelly W ^a   Coffin, Carla S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

hepatitis B immunoglobulin; hepatitis B virus; liver transplantation; postexposure prophylaxis; vertical transmission

Indexed keywords

ADEFOVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; TENOFOVIR;

ANTIBODY TITER; ARTICLE; BODY FLUID; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MONOTHERAPY; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; POST EXPOSURE PROPHYLAXIS; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; SEXUAL BEHAVIOR; VERTICAL TRANSMISSION; VIRUS CARRIER;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CLINICAL TRIALS AS TOPIC; DISEASE TRANSMISSION, INFECTIOUS; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B ANTIGENS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LIVER DISEASES; LIVER TRANSPLANTATION; OFF-LABEL USE; RECURRENCE;

EID: 79960924252     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.30     Document Type: Article

References (65)

1. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J. Med 351(27), 2832-2838 (2004) (Pubitemid 40051907)
2. Redeker AG, Mosley JW, Gocke DJ, McKee AP, Pollack W. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N Engl J. Med 293(21), 1055-1059 (1975)
3. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32(6), 1189-1195 (2000)
4. Schilling R, Ijaz S, Davidoff M et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol. 77(16), 8882-8892 (2003) (Pubitemid 36936099)
5. Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J. Aust. 190(9), 489-492 (2009)
6. Gane E. Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low, or no dose? Liver Transpl. 16(S2), S36-S39 (2010)
7. Mast EE, Margolis HS, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm. Rep. 54(RR-16), 1-31 (2005)
8. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm. Rep. 55(RR-16), 1-33; quiz CE1-4 (2006)
9. Hann HW, Hann RS, Maddrey WC. Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol. 102(4), 767-772 (2007) (Pubitemid 46496611)
10. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J. Med 294(14), 746-749 (1976)
11. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332(7537), 328-336 (2006)
12. Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus -a systematic review. Virol. J 5, 100 (2008)
13. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Abstract 235: A retrospective study for clinical outcome of caesarean section on perinatal transmission of Hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Hepatology 52(S1), 422A-522A (2010)
14. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet. Gynecol. 116(1), 147-159 (2010)
15. Bond WW, Petersen NJ, Favero MS. Viral hepatitis B: aspects of environmental control. Health Lab. Sci. 14(4), 235-252 (1977) (Pubitemid 8324740)
16. MacCannell T, Laramie AK, Gomaa A, Perz JF. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies. Clin Liver Dis. 14(1), 23-36, VII (2010)
17. Shikata T, Karasawa T, Abe K et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect. Dis. 136(4), 571-576 (1977) (Pubitemid 8211390)
18. U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm. Rep. 50(RR-11), 1-52 (2001)
19. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet 1(8219), 550-551 (1981)
20. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis -United States, 2007. MMWR Surveill. Summ. 58(3), 1-27 (2009)
21. Kennedy M, Alexopoulos SP. Hepatitis B virus infection and liver transplantation. Curr Opin. Organ. Transplant 15(3), 310-315 (2010)
22. Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol. 101(6), 1370-1378 (2006) (Pubitemid 43830007)
23. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 11(7), 716-732 (2005) (Pubitemid 40975571)
24. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 61(9), 1358-1364 (1996) (Pubitemid 26152826)
25. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24(6), 1327-1333 (1996) (Pubitemid 26399024)
26. Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg. 227(6), 841-850 (1998) (Pubitemid 29119531)
27. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 14(Suppl. 1), 37-44 (2007) (Pubitemid 47624113)
28. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int. 29(9), 1294-1305 (2009)
29. Golling M, Arnold JC, Rudek B et al. HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Transplant Proc. 30(7), 3316-3317 (1998) (Pubitemid 28538825)
30. So SK, Esquivel CO, Imperial JC, Garcia G, Monge H, Keeffe EB. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis? J. Gastroenterol. Hepatol. 14(Suppl.) S48-S52 (1999) (Pubitemid 29281866)
31. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 337(8745), 813-815 (1991)
32. Lemmens HP, Langrehr JM, Blumhardt G et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short-or long-term immunoprophylaxis. Transplant Proc. 26(6), 3622-3623 (1994)
33. Konig V, Hopf U, Neuhaus P et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 58(5), 553-559 (1994) (Pubitemid 24289845)
34. Targhetta S, Villamil F, Inturri P et al. Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J. Gastroenterol. 12(11), 1706-1712 (2006)
35. Gugenheim J, Baldini E, Ouzan D, Mouiel J. Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant Proc. 29(1-2), 517-518 (1997) (Pubitemid 27123514)
36. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33(2), 424-432 (2001) (Pubitemid 32119032)
37. Xia J, Wang YG, Wang YM. Efficacy of lamivudine for prevention of hepatitis B virus reinfection after liver transplantation. Chin. J Organ Transplant. 27, 167-169 (2006)
38. Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 6(6), 741-748 (2000)
39. Honaker MR, Shokouh-Amiri MH, Vera SR et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect. Dis. 4(3), 137-143 (2002) (Pubitemid 35364777)
40. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28(2), 585-589 (1998) (Pubitemid 28363690)
41. Sousa JM, Pareja F, Serrano J et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant Proc. 35(2), 723-724 (2003) (Pubitemid 36338133)
42. Neff GW, OBrien CB, Nery J et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl. 10(11), 1372-1378 (2004) (Pubitemid 39530052)
43. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77(8), 1203-1208 (2004) (Pubitemid 38580298)
44. Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg. 235(5), 611-619; discussion 619-620 (2002)
45. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132(3), 931-937 (2007) (Pubitemid 46440868)
46. Karademir S, Astarcioglu H, Akarsu M et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc. 38(2), 579-583 (2006)
47. Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 12(2), 253-258 (2006) (Pubitemid 43273784)
48. Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol. 38(6), 811-817 (2003) (Pubitemid 36613348)
49. Neff GW, Kemmer N, Kaiser TE et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig. Dis. Sci. 52(10), 2497-2500 (2007) (Pubitemid 47373893)
50. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 48(5), 1460-1466 (2008)
51. Cholongitas E, Papatheodoridis GV, Goulis I, Akriviadis E. Abstract 1151. Combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogue(s) [NUC(s)] for prophylaxis against posttransplant HBV recurrence: a systematic review. Hepatology 52(S1), 422A-522A (2010)
52. Teperman L, Spivey J, Poordad F et al. 28 emtricitabine/tenofovir DF combination +/-HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results. J Hepatol. 52(Suppl. 1), S12-S13 (2010)
53. Chen J, Yi L, Jia JD, Ma H, You H. Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review. J Gastroenterol. Hepatol. 25(5), 872-879 (2010)
54. Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect. Dis. 12(4), 292-308 (2010)
55. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50(3), 661-662 (2009)
56. Marzano A, Marengo A, Andreone P et al. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. Minerva Med. 101(6), 373-383 (2010)
57. Degertekin B, Han SH, Keeffe EB et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 10(8), 1823-1833 (2010)
58. Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol. 9(2), 166-171 (2010)
59. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from antihepatitis B core positive donors: a systematic review. J Hepatol. 52(2), 272-279 (2010)
60. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl. 16(3), 300-307 (2010)
61. Vizzini G, Gruttadauria S, Volpes R et al. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin Transplant 25(1), E77-E81 (2011)
62. Brock GN, Mostajabi F, Ferguson N et al. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl. Int. 24(6), 570-581 (2011)
63. Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus (HBV) quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl. DOI: 10.1002/lt.22312 (2011) (Epub ahead of print)
64. HepaGamB® Prescribing Information. Cangene bioPharma, Inc. Baltimore, MD, USA www.hepagamb.com/pdf/HepaGamBPI. pdf
65. Product Monograph HepaGam B®. Cangene Corporation, Winnipeg MB, Canada (2009) www.cangene.com/pdf/HepaGam%20 B%20English%20PM-APR%2023%20 2009.pdf